Transient receptor potential melastatin 7 kinase domain (TRPM7 kinase)

The transient receptor potential melastatin 7 (TRPM7) kinase domain is the C-terminal catalytic portion of a unique bifunctional protein known as a channenzyme. This domain belongs to the atypical alpha-kinase family and is covalently fused to a non-selective cation channel that is primarily permeable to magnesium and calcium. The kinase domain regulates various cellular processes by phosphorylating substrates such as myosin IIA, annexin A1, and eukaryotic elongation factor 2 (eEF2), thereby influencing the cytoskeleton and signal transduction pathways. In disease states, TRPM7 is heavily implicated in cancer progression, where its overexpression promotes tumor cell proliferation, migration, and metastasis. It also plays a significant role in ischemic brain injury, where its activation under conditions of ATP depletion leads to toxic cation influx and neuronal death. Pharmacological targeting of the kinase domain, such as with the inhibitor TG100-115, offers a strategy to modulate these pathological processes, although the protein's essential role in systemic magnesium homeostasis presents a significant therapeutic challenge.

Other names

TRP-PLIKChaK1LTRPC7ChannenzymeAlpha-kinase

Inhibition of the C-terminal alpha-kinase domain to prevent phosphorylation of downstream substrates (e.g., annexin A1, myosin IIA) and modulation of the associated cation channel activity to regulate magnesium and calcium influx.